Free Newsletter
Merck, Schering to cut 16,000 post-merger
Merck CEO Dick Clark spoke a figure, and around the world, people started worrying. That figure was 15 percent--the estimated job cuts attendant on his company's merger with Schering-Plough. With a combined workforce of 106,000, the two companies will together shed about 16,000 workers.
That's not a huge surprise; Clark was quoting billions of dollars in cost savings from the deal, and big mergers often do mean big layoffs. Consider the Pfizer-Wyeth deal, which is also expected to result in a 15 percent job loss, or some 19,500 cuts. But "expected" doesn't mean "easy." So forgive staffers in Ireland and England, in Philadelphia and New Jersey--probably in any location where Merck or Schering has workers--for their pink-slip nightmares.
The good news for Philly folks is that Clark calls the impact there "minimal." That's because there's little if any overlap between the two companies in that area. Not so much in New Jersey, where both companies maintain their headquarters. For instance, in Schering's home base of Kenilworth, local officials and small business owners were stunned by the announcement, because the tax base and commerce there depend on the drugmaker. It's the biggest game in town.
We'll have to wait some months to see just where the layoffs take place. But in the meantime, we expect plenty of résumès to fly out of both companies. Just in case.
- read the article in the Philadelphia Inquirer
- see the New York Times New Jersey piece
- get more on Kenilworth from the NYT
- check out the Manchester Journal's coverage
- read the Irish Times story
Related Articles:
Merck nabs Schering-Plough in $41.1B deal
Merck, Schering swing to 4Q profit
Merck - Top 5 layoffs of 2008
Schering-Plough - Top 5 layoffs of 2008
Comments
SP people have lived through and come out of the consent decree - with a great pipeline. Lots of hard, smart work. Unfortunately, all that work "to earn trust, every day" was actually to earn Fred's retirement. This will cause incalculable misery, and threatens the productive R&D at SP...mostly because the actual surviving company will be too arrogant to learn from SP researchers. Who generated the pipeline...? Another R&D engine will be destroyed, following in the Pfizer model of "integration."
Post new comment
Paid Research Reports
- The Specialty Pharma Market Outlook: Key players, new company growth models and emerging opportunities
- Investigating Clinical Trial Costs: Comparative analysis of trial cost components in key geographies
- Clinical Trial Recruitment Strategies: Optimizing patient recruitment and retention in late stage clinical trials
- Pipeline Insight: Therapeutic Cancer Vaccines - Prospect of first approval set to reinvigorate interest from major companies
- Stakeholder Opinions: Vaccines in Emerging Markets (Asia) - Opportunities in China, India, South Korea and Taiwan
- Big Pharma Performance Before, During and Beyond the Global Recession





